You are here

Elvitegravir/cobicistat/emtricitabine/tenofovir DF (STB) has durable efficacy and differentiated safety compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF at week 144 in treatment-naive HIV-1 infected patients

TitleElvitegravir/cobicistat/emtricitabine/tenofovir DF (STB) has durable efficacy and differentiated safety compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF at week 144 in treatment-naive HIV-1 infected patients
Publication TypeConference Paper
Year of Publication2013
AuthorsClumeck N., Molina J., Henry K., Gathe J., Rockstroh J., DeJesus E., Wei X., White K., Fordyce M., Rhee M., Szwarcberg J.
Conference Name14th European AIDS Conference
Date Published10/2013
PublisherEuropean Clinical AIDS Society
Conference LocationBrussels, Belgium
Other NumbersAbstract LBPS7/2
URLhttp://www.natap.org/2013/EACS/EACS_08.htm